Quantum-Enhanced Predictive Genomics Market Report 2025

The quantum-enhanced predictive genomics market size has grown exponentially in recent years. It will grow from $1.45 billion in 2024 to $1.95 billion in 2025 at a compound annual growth rate (CAGR) of 34.1%. The growth during the historic period is driven by rising demand for precision medicine, increasing complexity of genomic data, growing investments in quantum computing, expanding applications in disease prediction, and stronger collaborations between technology and healthcare sectors.

The quantum-enhanced predictive genomics market size is expected to see exponential growth in the next few years. It will grow to $6.26 billion in 2029 at a compound annual growth rate (CAGR) of 33.8%. The projected growth in the forecast period is supported by wider adoption of personalized healthcare, greater integration of AI with quantum genomics, increased focus on early disease detection, rising government and private R&D funding, and broader availability of advanced genomic datasets. Key trends in this period include advancements in quantum machine learning models, innovations in genomic data encryption and security, integration of multi-omics with quantum analytics, development of cloud-based quantum genomics platforms, and collaborations between quantum technology firms and biotechnology companies.

The increasing demand for personalized medicine is anticipated to drive the growth of the quantum-enhanced predictive genomics market. Personalized medicine involves tailoring medical care, treatments, and prevention strategies based on an individual's unique genetic, biological, and clinical profile. The rise in demand for personalized medicine is largely due to its ability to improve treatment effectiveness. Therapies that are tailored to a patient's genetic makeup often lead to better outcomes and fewer side effects. Quantum-enhanced predictive genomics plays a key role in this by enabling ultra-fast analysis of complex genomic data, which allows clinicians to develop highly precise and individualized treatment plans. For example, in 2024, NHS England reported that over 810,000 personalized genomic tests were delivered to patients through the NHS genomic medicine service, an 8% increase from the previous year, reflecting the growing demand for genomic-led care. As a result, the demand for personalized medicine is expected to fuel the growth of the quantum-enhanced predictive genomics market.

Leading companies in the quantum-enhanced predictive genomics market are focusing on innovations such as high-throughput genomic data processing to speed up the identification of genetic variations, enhance predictive accuracy in personalized medicine, and enable faster, more precise analysis of complex genomic datasets. High-throughput genomic data processing refers to the rapid, large-scale analysis of genomic sequences using advanced computational methods. For instance, in June 2025, Norma Group, a Germany-based company specializing in engineered and standardized joining and fluid-handling technology, partnered with Seoul National University Bundang Hospital (SNUBH) to apply quantum algorithms to large-scale genomic analysis. The collaboration aims to accelerate the detection of genetic mutations through quantum-enhanced combinatorial optimization, enhancing both the speed and accuracy of genomic data processing beyond classical computing methods. Key applications include precision diagnostics, personalized treatment planning, and genetic risk assessment for diseases such as cancer and neurological disorders.

In August 2025, Quantinuum, a UK-based software company, teamed up with the Wellcome Sanger Institute to advance quantum computing applications in genomics. This partnership is part of the Sanger Institute’s Wellcome Leap Quantum for Bio (Q4Bio) challenge, a global initiative aimed at supporting research in quantum-based genomic analysis. The Wellcome Sanger Institute is focused on developing quantum-enhanced predictive genomics solutions.

Major players in the quantum-enhanced predictive genomics market are Google LLC, Microsoft Corporation, Alibaba Group Holding Limited, Amazon Web Services Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Accenture plc, IBM Corporation, Pfizer Inc., Bayer AG, AstraZeneca plc, GlaxoSmithKline plc, Honeywell International Inc., Fujitsu Limited, Eviden, Xanadu Quantum Technologies Inc., Pasqal SA, Rigetti Computing Inc., IonQ Inc., D-Wave Systems Inc.

North America was the largest region in the quantum-enhanced predictive genomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in quantum-enhanced predictive genomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the quantum-enhanced predictive genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Quantum-enhanced predictive genomics involves using quantum computing to analyze complex genomic data, enabling faster and more precise predictions of disease risk, treatment response, and other health outcomes. This approach identifies patterns in large-scale genetic datasets that conventional methods may overlook, supporting biomarker discovery and personalized medicine.

The primary technologies in quantum-enhanced predictive genomics include quantum computing, quantum machine learning, quantum cryptography, and related tools. Quantum computing consists of advanced computational platforms designed for rapid analysis and interpretation of complex genomic datasets. These solutions can be deployed in cloud-based or on-premises environments and are used by pharmaceutical and biotechnology companies, research institutes, healthcare providers, and other organizations engaged in genomics and precision medicine.

The quantum-enhanced predictive genomics market research report is one of a series of new reports that provides quantum-enhanced predictive genomics market statistics, including the quantum-enhanced predictive genomics industry global market size, regional shares, competitors with the quantum-enhanced predictive genomics market share, detailed quantum-enhanced predictive genomics market segments, market trends, and opportunities, and any further data you may need to thrive in the quantum-enhanced predictive genomics industry. This quantum-enhanced predictive genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The quantum-enhanced predictive genomics market consists of revenues earned by entities by providing services such as clinical decision support services, oncology-focused predictive genomics services, and multi-omics integration services. The market value includes the value of related goods sold by the service provider or included within the service offering. The quantum-enhanced predictive genomics market includes sales of quantum-powered epigenetic predictive tools, quantum-integrated personalized preventive health tools, and quantum-enhanced synthetic biology design platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.